Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (101-110 of 137) with videos related to

Pageof 14
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2013
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysisHeather J Ribaudo, Kimberly Y Smith, Gregory K Robbins, et al.
Journal of Mass Spectrometry : JMS|January 25, 2011
Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric methodLing-Zhi Wang, Lawrence Soon-U Lee, Win-Lwin Thuya, et al.
Journal of Materials Chemistry. B|November 13, 2023
Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabineChung Liu, Faye Y Hern, Anika Shakil, et al.
Journal of Virology|May 23, 2008
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subjectAthe M N Tsibris, Manish Sagar, Roy M Gulick, et al.
Archives of Internal Medicine|July 15, 2009
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trialRobert Gross, Camlin Tierney, Adriana Andrade, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2007
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211Timothy J Wilkin, Zhaohui Su, Daniel R Kuritzkes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
AIDS Research and Human Retroviruses|December 16, 2004
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307Ian Frank, Ronald J Bosch, Susan Fiscus, et al.
Planta Medica|March 28, 2009
Induction of chemoprotective phase 2 enzymes by ginseng and its componentsLawrence S Lee, Katherine K Stephenson, Jed W Fahey, et al.
The Journal of Infectious Diseases|October 31, 2009
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211Zhaohui Su, Roy M Gulick, Amy Krambrink, et al.
Pageof 14

Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2013
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysisHeather J Ribaudo, Kimberly Y Smith, Gregory K Robbins, et al.
Journal of Mass Spectrometry : JMS|January 25, 2011
Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric methodLing-Zhi Wang, Lawrence Soon-U Lee, Win-Lwin Thuya, et al.
Journal of Materials Chemistry. B|November 13, 2023
Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabineChung Liu, Faye Y Hern, Anika Shakil, et al.
Journal of Virology|May 23, 2008
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subjectAthe M N Tsibris, Manish Sagar, Roy M Gulick, et al.
Archives of Internal Medicine|July 15, 2009
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trialRobert Gross, Camlin Tierney, Adriana Andrade, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2007
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211Timothy J Wilkin, Zhaohui Su, Daniel R Kuritzkes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
AIDS Research and Human Retroviruses|December 16, 2004
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307Ian Frank, Ronald J Bosch, Susan Fiscus, et al.
Planta Medica|March 28, 2009
Induction of chemoprotective phase 2 enzymes by ginseng and its componentsLawrence S Lee, Katherine K Stephenson, Jed W Fahey, et al.
The Journal of Infectious Diseases|October 31, 2009
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211Zhaohui Su, Roy M Gulick, Amy Krambrink, et al.
Pageof 14